Frontiers in Oncology (Nov 2023)

Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma

  • Heejune So,
  • Hyunjong Lee,
  • Seung Hyup Hyun,
  • Young Seok Cho,
  • Seung Hwan Moon,
  • Joon Young Choi,
  • Kyung-Han Lee

DOI
https://doi.org/10.3389/fonc.2023.1283582
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundTotal metabolic tumor volume (TMTV) in 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) predicts patient outcome in follicular lymphoma (FL); however, it requires laborious segmentation of all lesions. We investigated the prognostic value of the metabolic bulk volume (MBV) obtained from the single largest lesion.MethodsPretreatment FDG PET/computed tomography (CT) scans of 201 patients were analyzed for TMTV and MBV using a 41% maximum standardized uptake value (SUVmax) threshold.ResultsDuring a median follow-up of 3.2 years, 54 events, including 14 deaths, occurred. Optimal cut-offs were 121.1 cm3 for TMTV and 24.8 cm3 for MBV. Univariable predictors of progression-free survival (PFS) included a high Follicular Lymphoma International Prognostic Index 2 (FLIPI2) score, TMTV, and MBV. In the multivariable analysis, high TMTV and MBV were independent predictors of worse PFS (P =0.015 and 0.033). Furthermore, in a sub-group with FLIP2 scores of 0–2 (n = 132), high MBV could identify patients with worse PFS (P = 0.007). ConclusionReadily measurable MBV is useful for stratifying risk in FL patients.

Keywords